(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

GMP ORPHAN DRUGS FOR ORPHAN DISEASES

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

GMP ORPHAN DRUGS FOR ORPHAN DISEASES

ST13

US500000079134010

Classe

5, 10, 42, 44

Pedido

79134010

Registro

4541221

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

42

Atualização mais recente

31/03/2026

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5, 10, 42, 44

Data de depósito

14/05/2013

Data de registro

03/06/2014

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

06/03/2026

Última transação

31/03/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

99

Localização do titular

FR

Examinador

SPRUILL, DARRYL M

Unidade examinadora

M30

Descrição da marca

The mark consists of the literal stylized wording "gmp orphan drugs for orphan diseases". The wording "gmp" and "drugs for orphan diseases" appear in the color white, and the wording "orphan" is in black. The wording "gmp" is displayed with the letter "o" of the wording "orphan" above the wording "drugs for orphan diseases" all in a blue box, and the letters "rphan" appear outside of the box.

Titulares e representantes

Titulares

ORPHALAN
GMP-ORPHAN

Representantes

Heather Smith-Carra Banner & Witcoff, Ltd.

Classificação técnica

Classes Nice

Classe 5Classe 10Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceutical and veterinary products for the treatment of orphan diseases; medication for the treatment of orphan diseases; pharmaceutical and veterinary products for pediatric use for the treatment of orphan diseases; medication for pediatric use for the treatment of orphan diseases; chemical preparations for medical or pharmaceutical use in the treatment of childhood diseases; pharmaceutical and veterinary products and medicines for the treatment of orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy; pharmaceutical and veterinary products and medicines for the treatment of hyperammonemia of all kinds

Classe 10

[ Medical, surgical and veterinary apparatus and instruments, for diagnosis and treatment, particularly in connection with orphan diseases; medical devices containing chemical products for diagnostic use of orphan diseases; medical diagnosis apparatus and instruments to diagnose orphan diseases; automatic testing apparatus to diagnose orphan diseases, for medical use, also in the form of kits; medical apparatus and instruments in the form of kits for detecting the presence of analytes in biological fluids, other fluids and other structures; immunochemical testing apparatus for medical use; blood testing apparatus; radiological apparatus for medical use; resuscitation apparatus; medical imaging apparatus incorporating medical imaging software; needles for medical use; gloves for medical use; syringes for medical use; inhalers for medical purposes; injectors for medical use; X-ray photographs for medical use; radiology screens for medical use; receptacles for applying medicines; containers especially made for medical waste; probes for medical use; stethoscopes; heart pacemakers; thermometers for medical use; cases fitted for medical instruments for use by surgeons or doctors ]

Classe 42

Evaluations, assessments and research in the fields of science; research and development services in the field of medicine; research and development of new products for others, namely, medical diagnosis apparatus; research and development in the field of biotechnology; scientific research for medical purposes; scientific laboratory services in the medical field; all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy

Classe 44

Medical services; medical and sanitary care, namely, telemedecine services including remote diagnosis or medical follow-up; medical testing for the diagnosis and treatment of persons; providing medical advice on health matters in the field of medication administration; providing medical advisory services relating to medical apparatus and instruments; medical diagnosis services of orphan diseases; providing medical information, all the aforesaid services in connection with the treatment of childhood and orphan diseases, particularly spinal muscular atrophy, sickle-cell anemia, progressive nuclear palsy, amyotrophic lateral sclerosis (ALS), cystic fibrosis, Duchenne muscular dystrophy, macrophagic myofasciitis, lysosomal storage disease, leukodystrophy

Publicações

Histórico de despachos e eventos da marca no USPTO.

42 publicações encontradas

C71T

CANCELLED SECTION 71

06/03/2026

RNWL

INTERNATIONAL REGISTRATION RENEWED

09/06/2023

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

03/06/2023

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

05/12/2021

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

27/10/2021

INPC

INVALIDATION PROCESSED

27/10/2021

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

06/10/2021

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

06/02/2021

71.P

REGISTERED - PARTIAL SEC 71 ACCEPTED

06/02/2021

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

01/02/2021

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

29/01/2021

ES71

TEAS SECTION 71 RECEIVED

03/12/2020

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

03/06/2019

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/02/2019

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

08/02/2018

NREP

NEW REPRESENTATIVE AT IB RECEIVED

03/03/2016

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

21/11/2014

FICS

FINAL DISPOSITION NOTICE SENT TO IB

21/10/2014

FIMP

FINAL DISPOSITION PROCESSED

21/10/2014

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

03/09/2014

R.PR

REGISTERED-PRINCIPAL REGISTER

03/06/2014

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

18/03/2014

PUBO

PUBLISHED FOR OPPOSITION

18/03/2014

GPNX

NOTIFICATION PROCESSED BY IB

14/03/2014

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

26/02/2014

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

26/02/2014

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

26/02/2014

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

07/02/2014

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

05/02/2014

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/02/2014

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/02/2014

ALIE

ASSIGNED TO LIE

30/01/2014

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

22/01/2014

RFNT

REFUSAL PROCESSED BY IB

30/09/2013

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

11/09/2013

RFRR

REFUSAL PROCESSED BY MPU

11/09/2013

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

11/09/2013

CNRT

NON-FINAL ACTION WRITTEN

10/09/2013

DOCK

ASSIGNED TO EXAMINER

03/09/2013

MAFR

APPLICATION FILING RECEIPT MAILED

16/08/2013

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/08/2013

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

08/08/2013

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace GMP ORPHAN DRUGS FOR ORPHAN DISEASES ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.